<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01186809</url>
  </required_header>
  <id_info>
    <org_study_id>Eudract number: 2008-003185-26</org_study_id>
    <nct_id>NCT01186809</nct_id>
  </id_info>
  <brief_title>Cytokine Induced Killer (CIK) Cells In Leukemia Patients</brief_title>
  <acronym>CIK2</acronym>
  <official_title>Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)Cells After Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regional Hospital of Bolzano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Phase IIA study are to:

        1. define the safety profile

        2. evaluate the efficacy of a sequential infusion of unmanipulated Donor Lymphocyte
           Infusions (DLI) and Cytokine Induced Killer (CIK) cells for the treatment of molecular,
           cytogenetic or hematologic relapse after hematopoietic stem cell transplantation and The
           progression free survival and the overall survival after the sequential infusion of
           Donor Lymphocyte Infusions (DLI) and Cytokine Induced Killer(CIK) cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label, multicenter, exploratory phase IIA study to evaluate the safety
      (dose-finding) and efficacy of a sequential administration of donor derived unmanipulated DLI
      and in vitro expanded Cytokine Induced Killer(CIK) cells.

      Two infusions of unmanipulated donor lymphocytes (1x106/Kg each) will be given with a minimum
      interval of 3 weeks. Three infusions of donor Cytokine Induced Killer (CIK) cells will be
      administered according to a dose escalating program, starting 3 weeks after second Donor
      Lymphocyte Infusions (DLI). In presence of grade 2 or more acute graft versus host
      disease(GVHD), the patient will not receive the next scheduled infusion. Only grade 4 acute
      graft versus host disease (aGVHD) is considered for the dose limiting toxicity (DLT). Once
      identified the maximally tolerated dose (MTD), this same combination of doses will be
      administered up to 24 patients in a two-stage minimax design.

      Primary Endpoints

      The primary endpoints of the Phase IIA study are:

        1. the Maximally Tolerated Dose (MTD) - (safety end-point)

        2. the cumulative incidence of molecular, karyotypic or haematologic responses at day +100
           after the end of the cell therapy program - (efficacy end-point)

      Secondary Endpoints Progression Free Survival (PFS) Progression Free Survival (PFS) will be
      defined as any evidence of molecular, cytogenetic or haematologic disease progression.
      Cytogenetic and/or molecular relapse will be defined where available as any evidence of a
      pre-transplant defined abnormality using conventional cytogenetics or FISH techniques or
      molecular probes. Assessments will be performed at 1 year after the end of the cell therapy
      program Overall Survival (OS) The Overall Survival(OS) will be assessed by 1 year after the
      end of the cell therapy program. For assessment of the Overall Survival (OS), events will be
      deaths for any causes, patients being censored if alive.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 15, 2017</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Measures</measure>
    <time_frame>Clinical response was measured at 100 days after the completion of the cell therapy program.</time_frame>
    <description>The occurrence of a grade 4 acute graft versus host disease (GVHD), judged to be related to the study medication. Grading and staging will be performed using the Glucksberg scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Measures</measure>
    <time_frame>The clinical response will be registered at day +100 after the last Cytokine Induced Killer (CIK) cell infusion</time_frame>
    <description>The proportion of patients achieving a complete, a partial or a hematologic improvement in responses to the experimental infusion of cytokine induced killer (CIK)cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Cytokine Induced Killer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>in vitro expanded Cytokine Induced Killer (CIK) cells</intervention_name>
    <description>Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals</description>
    <arm_group_label>Cytokine Induced Killer</arm_group_label>
    <other_name>patients will be offered Cytokine Induced Killer(CIK) cells.</other_name>
    <other_name>Four combinations of escalating Cytokine Induced Killer (CIK) cells infusions will be provided, until the MTD will be defined.</other_name>
    <other_name>Combination 1st CIK cells infusion 2nd CIK cells infusion 3rd CIK cells infusion</other_name>
    <other_name>1 1x106/Kg 1x106/Kg 5x106/kg</other_name>
    <other_name>2 1x106/Kg 5x106/kg 5x106/kg</other_name>
    <other_name>3 1x106/Kg 5x106/kg 10x106/kg</other_name>
    <other_name>4 5x106/kg 5x106/kg 10x106/kg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with haematologic malignancies (excluding chronic myeloid Leukemia- CML) with
             a molecular, cytogenetic or haematologic relapse after allogeneic transplantation.

          -  Patients with an available donor willing to donate peripheral blood lymphocytes

          -  Immunosuppression must be withdrawn at the beginning of the cell therapy program

          -  Written informed consent prior to any study procedures being performed

        Exclusion Criteria:

          -  Donors positive for HIV, HBV or HCV, or unfit to undergo leukapheresis

          -  Patients with active acute or chronic Graft versus host disease (GvHD)

          -  Patients with rapidly progressive disease or not controlled by palliative supportive
             treatments including chemotherapy and with a life expectancy less than 8 weeks

          -  Patients with severe psychiatric illness or any disorder that compromises ability to
             give truly informed consent for participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro AR Rambaldi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Papa Giovanni XXIII (Former:Ospedali Riuniti di Bergamo)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII (Former:Ospedali Riuniti di Bergamo) Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Centrale di Bolzano</name>
      <address>
        <city>Bolzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, Rambaldi A. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant. 2006 Nov;38(9):621-7. Epub 2006 Sep 18.</citation>
    <PMID>16980990</PMID>
  </results_reference>
  <results_reference>
    <citation>Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007 Jul;92(7):952-9.</citation>
    <PMID>17606446</PMID>
  </results_reference>
  <results_reference>
    <citation>Capelli C, Salvade A, Pedrini O, Barbui V, Gotti E, Borleri G, Cabiati B, Belotti D, Perseghin P, Bellavita P, Biondi A, Biagi E, Rambaldi A, Golay J, Introna M. The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. Cytotherapy. 2009;11(4):403-13. doi: 10.1080/14653240902960437.</citation>
    <PMID>19462317</PMID>
  </results_reference>
  <results_reference>
    <citation>Introna M, Pievani A, Borleri G, Capelli C, Algarotti A, Mic√≤ C, Grassi A, Oldani E, Golay J, Rambaldi A. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation. Biol Blood Marrow Transplant. 2010 Nov;16(11):1603-7. doi: 10.1016/j.bbmt.2010.05.015. Epub 2010 Jun 1.</citation>
    <PMID>20685246</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2010</study_first_posted>
  <results_first_submitted>June 20, 2017</results_first_submitted>
  <results_first_submitted_qc>January 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 23, 2019</results_first_posted>
  <last_update_submitted>January 17, 2019</last_update_submitted>
  <last_update_submitted_qc>January 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>A.O. Ospedale Papa Giovanni XXIII</investigator_affiliation>
    <investigator_full_name>Rambaldi Alessandro</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>hematologic malignancies (excluding Chronic Myeloid Leukemia)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>final report</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 74 patients were enrolled in the study from July 2009 to September 2016</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cytokine Induced Killer</title>
          <description>Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
in vitro expanded Cytokine Induced Killer (CIK) cells: Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
This is a phase IIA study to evaluate the safety (dose-finding) and efficacy of a sequential administration of donor derived unmanipulated DLI and in vitro expanded CIK cells. Two infusions of unmanipulated donor lymphocytes (1x106/Kg each) will be given with a minimum interval of 3 weeks. Three infusions of donor CIK cells will be administered according to a dose escalating program, starting 3 weeks after second DLI. CIK administrations will be separated by 3 weeks intervals. Standard treatment with unmanipulated DLI will be offered to patients refusing the proposal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cytokine Induced Killer</title>
          <description>Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
in vitro expanded Cytokine Induced Killer (CIK) cells: Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Measures</title>
        <description>The occurrence of a grade 4 acute graft versus host disease (GVHD), judged to be related to the study medication. Grading and staging will be performed using the Glucksberg scale</description>
        <time_frame>Clinical response was measured at 100 days after the completion of the cell therapy program.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cytokine Induced Killer</title>
            <description>Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
in vitro expanded Cytokine Induced Killer (CIK) cells: Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
This is a phase IIA study to evaluate the safety (dose-finding) and efficacy of a sequential administration of donor derived unmanipulated DLI and in vitro expanded CIK cells. Two infusions of unmanipulated donor lymphocytes (1x106/Kg each) will be given with a minimum interval of 3 weeks. Three infusions of donor CIK cells will be administered according to a dose escalating program, starting 3 weeks after second DLI. CIK administrations will be separated by 3 weeks intervals. Standard treatment with unmanipulated DLI will be offered to patients refusing the proposal.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Measures</title>
          <description>The occurrence of a grade 4 acute graft versus host disease (GVHD), judged to be related to the study medication. Grading and staging will be performed using the Glucksberg scale</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Measures</title>
        <description>The proportion of patients achieving a complete, a partial or a hematologic improvement in responses to the experimental infusion of cytokine induced killer (CIK)cells</description>
        <time_frame>The clinical response will be registered at day +100 after the last Cytokine Induced Killer (CIK) cell infusion</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>three years;</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cytokine Induced Killer</title>
          <description>Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK)
in vitro expanded Cytokine Induced Killer (CIK) cells: Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
This is a phase IIA study to evaluate the safety (dose-finding) and efficacy of a sequential administration of donor derived unmanipulated DLI and in vitro expanded CIK cells. Two infusions of unmanipulated donor lymphocytes (1x106/Kg each) will be given with a minimum interval of 3 weeks. Three infusions of donor CIK cells will be administered according to a dose escalating program, starting 3 weeks after second DLI. CIK administrations will be separated by 3 weeks intervals. Standard treatment with unmanipulated DLI will be offered to patients refusing the proposal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>hemolitic anemia</sub_title>
                <description>severe hemolitic anemia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>aGVHD grade III; IV</sub_title>
                <description>acute graft versus host disease</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>severe chronic GVHD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>aGvHD</sub_title>
                <description>grade 1-2 acute graft versus host disease</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>cGvHD</sub_title>
                <description>mild and moderate chronic graft versus host disease</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Alessandro Rambaldi</name_or_title>
      <organization>Asst Papa Giovanni XXIII</organization>
      <phone>+390352673681</phone>
      <email>arambaldi@asst-pg23.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

